Epinephrine self-injectable - kaleo

Drug Profile

Epinephrine self-injectable - kaleo

Alternative Names: Allerject; Auvi-Q; e-cue

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator Intelliject
  • Developer kaleo; Sanofi
  • Class Antiarrhythmics; Antihaemorrhagics; Antihypotensives; Bronchodilators; Catecholamines; Ethanolamines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaphylaxis; Hypersensitivity

Most Recent Events

  • 23 Feb 2016 Sanofi and kaleo will terminate the license and development agreement by the end of 2016
  • 28 Oct 2015 Sanofi recalls all existing lots of Allerject® and Auvi-Q™ from Canada and USA because of inaccurate dosage delivery ,,
  • 06 Jan 2014 Intelliject is now called kaleo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top